ESC 2023 | ECLS-Shock

Cardiogenic shock (CS) represents the main cause of death in patients hospitalized for acute myocardial infarction (AMI). Despite advances in its management, mortality continues to be high, between 40-50% within the first 30 days. In an attempt to improve survival, early extracorporeal life support (ECLS) is being increasingly used to stabilized hemodynamics in cases of serious shock, especially the use of venoarterial extracorporeal membrane oxygenation (VA-ECMO), also called ECLS. 

ESC 2023

Evidence on the efficacy of VA-ECMO in the context of AMI and CS is based mainly on observational studies or small randomized trials. The ECLS-SHOCK is the first randomized clinical trial on VA-ECMO to look into mortality in patients with CS undergoing early revascularization. The study included patients from centers in Germany and Slovenia, mean age 63, and 19% were women.

Primary end point was all-cause mortality at 30 days. Secondary end points included length of mechanical ventilation, time to hemodynamic stabilization and need for renal replacement therapy. As regards safety, researchers looked into bleeding events (from moderate to severe) and peripheral vascular complications requiring intervention. 

Read also: ESC 2023 | STOPDAPT-3.

The final analysis considered a total of 417 patients. Primary end point occurred in 47.8% patients in the VA-ECMO group and 49% in the control group ([RR] 0.98, CI 95%, 0.80-1.19; p=0.81). Length of mechanical ventilation was higher in the VA-ECMO group (7 vs 5 days). Also, time to hemodynamic stabilization and need for renal replacement therapy rate were similar.  

As regards safety end points, there were more bleeding events in the VA-ECMO group (RR 2.44, CI 95% 1.50-3.95) and more interventions for peripheral vascular complications (RR 2.86, CI 95% 1.31-6.25).

Dr. Omar Tupayachi

Dr. Omar Tupayachi.
Member of the Editorial Board of SOLACI.org.

Source: Presented at the Hot Line Sessions, Agosto 26, ESC Congreess 2023, Amsterdam.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Plaque Ruptures in Non-Culprit Arteries: Follow-Up With Intravascular Imaging

Plaque rupture remains one of the most important pathophysiological mechanisms in acute coronary syndromes. However, not all ruptures manifest clinically as ischemia, myocardial infarction,...

OCT-Detected High-Risk Plaques Predict Recurrent Events After Myocardial Infarction

After a myocardial infarction (MI), non-culprit lesions are often deferred when they are not flow-limiting (negative FFR). However, these lesions continue to represent an...

Ticagrelor vs Clopidogrel in ACS Patients Receiving DOAC After PCI: More Bleeding Without Ischemic Benefit?

In patients with acute coronary syndrome (ACS) who require direct oral anticoagulation (DOAC) and undergo percutaneous coronary intervention (PCI), current guidelines recommend a dual...

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

Plaque Ruptures in Non-Culprit Arteries: Follow-Up With Intravascular Imaging

Plaque rupture remains one of the most important pathophysiological mechanisms in acute coronary syndromes. However, not all ruptures manifest clinically as ischemia, myocardial infarction,...

Drug-Eluting Stents in Peripheral Arterial Disease: When Should They Be Used?

Peripheral drug-eluting stents have transformed the treatment of peripheral arterial disease by reducing restenosis rates and the need for repeat interventions. However, the emergence...

OCT-Detected High-Risk Plaques Predict Recurrent Events After Myocardial Infarction

After a myocardial infarction (MI), non-culprit lesions are often deferred when they are not flow-limiting (negative FFR). However, these lesions continue to represent an...